Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016

  • ID: 3981251
  • Report
  • 108 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Argos Therapeutics Inc
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Cold Genesys Inc
  • F. Hoffmann-La Roche Ltd
  • MORE
Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016

Summary

Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides an overview of the Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline landscape.

Muscle-invasive disease is a type of bladder cancer which is much more likely to spread to other parts of the body Symptoms includes blood in the urine and pain when passing urine. Risk factors include use of tobacco, family history, exposure to arsenic, and infections. Treatment includes removing the bladder or treating the bladder with radiation and chemotherapy.

Report Highlights

Muscle Invasive Bladder Cancer (MIBC) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Muscle Invasive Bladder Cancer (MIBC) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Muscle Invasive Bladder Cancer (MIBC) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Muscle Invasive Bladder Cancer (MIBC) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Muscle Invasive Bladder Cancer (MIBC) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Muscle Invasive Bladder Cancer (MIBC) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Muscle Invasive Bladder Cancer (MIBC) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Argos Therapeutics Inc
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Cold Genesys Inc
  • F. Hoffmann-La Roche Ltd
  • MORE
List of Tables

List of Figures

Introduction

Muscle Invasive Bladder Cancer (MIBC) Overview

Therapeutics Development

Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Overview

Pipeline Products for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis

Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Development by Companies

Muscle Invasive Bladder Cancer (MIBC) - Therapeutics under Investigation by Universities/Institutes

Muscle Invasive Bladder Cancer (MIBC) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Muscle Invasive Bladder Cancer (MIBC) - Products under Development by Companies

Muscle Invasive Bladder Cancer (MIBC) - Products under Investigation by Universities/Institutes

Muscle Invasive Bladder Cancer (MIBC) - Companies Involved in Therapeutics Development

Argos Therapeutics Inc

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Cold Genesys Inc

F. Hoffmann-La Roche Ltd

MedImmune LLC

Oncolytics Biotech Inc

Sillajen Biotherapeutics

Taris Biomedical LLC

Muscle Invasive Bladder Cancer (MIBC) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

atezolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-1775 + durvalumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-4547 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CG-0070IT - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

durvalumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

erlotinib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gemcitabine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guadecitabine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTG-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pelareorep - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexastimogene devacirepvec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rocapuldencel-T - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects

Muscle Invasive Bladder Cancer (MIBC) - Product Development Milestones

Featured News & Press Releases

Jul 13, 2016: TARIS Biomedical Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS) in Patients with Muscle-Invasive Bladder Cancer

Jun 08, 2015: Oncolytics Biotech Provides Update at AGM on Planned Registration Program for REOLYSIN

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016

Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Argos Therapeutics Inc, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astellas Pharma Inc, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Astex Pharmaceuticals Inc, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline by AstraZeneca Plc, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Cold Genesys Inc, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline by MedImmune LLC, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Oncolytics Biotech Inc, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Sillajen Biotherapeutics, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Pipeline by Taris Biomedical LLC, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Muscle Invasive Bladder Cancer (MIBC) - Dormant Projects, H2 2016

List of Figures

Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC), H2 2016

Number of Products under Development for Muscle Invasive Bladder Cancer (MIBC) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Argos Therapeutics Inc
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Cold Genesys Inc
  • F. Hoffmann-La Roche Ltd
  • MedImmune LLC
  • Oncolytics Biotech Inc
  • Sillajen Biotherapeutics
  • Taris Biomedical LLC
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll